Supplementary Data S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Article Swipe
Jena D. French
,
Bryan R. Haugen
,
Francis P. Worden
,
Daniel W. Bowles
,
Andrew G. Gianoukakis
,
Bhavana Konda
,
Ramona Dadu
,
Eric J. Sherman
,
Shaylene McCue
,
Nathan R. Foster
,
Yuri E. Nikiforov
,
Ticiana D.J. Farias
,
Paul J. Norman
,
Lori J. Wirth
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.26926236.v1
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.26926236.v1
Clinical Trial Protocol
Related Topics
Concepts
Lenvatinib
Pembrolizumab
Medicine
Refractory (planetary science)
Oncology
Thyroid carcinoma
Targeted therapy
Radioiodine therapy
Internal medicine
Thyroid cancer
Cancer research
Thyroid
Immunotherapy
Cancer
Biology
Astrobiology
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.26926236.v1
- OA Status
- gold
- References
- 32
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4402200829
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4402200829Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.26926236.v1Digital Object Identifier
- Title
-
Supplementary Data S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid CancersWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-09-03Full publication date if available
- Authors
-
Jena D. French, Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis, Bhavana Konda, Ramona Dadu, Eric J. Sherman, Shaylene McCue, Nathan R. Foster, Yuri E. Nikiforov, Ticiana D.J. Farias, Paul J. Norman, Lori J. WirthList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.26926236.v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.26926236.v1Direct OA link when available
- Concepts
-
Lenvatinib, Pembrolizumab, Medicine, Refractory (planetary science), Oncology, Thyroid carcinoma, Targeted therapy, Radioiodine therapy, Internal medicine, Thyroid cancer, Cancer research, Thyroid, Immunotherapy, Cancer, Biology, AstrobiologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
32Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4402200829 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.26926236.v1 |
| ids.doi | https://doi.org/10.1158/1078-0432.26926236.v1 |
| ids.openalex | https://openalex.org/W4402200829 |
| fwci | 0.0 |
| type | preprint |
| title | Supplementary Data S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10329 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9986000061035156 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Thyroid Cancer Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T12030 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9520000219345093 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | S100 Proteins and Annexins |
| topics[2].id | https://openalex.org/T10631 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9280999898910522 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Cancer, Hypoxia, and Metabolism |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776264508 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9501677751541138 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q6523413 |
| concepts[0].display_name | Lenvatinib |
| concepts[1].id | https://openalex.org/C2780057760 |
| concepts[1].level | 4 |
| concepts[1].score | 0.895641565322876 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[1].display_name | Pembrolizumab |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.697416365146637 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C142424586 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6726108193397522 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7307572 |
| concepts[3].display_name | Refractory (planetary science) |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5956301689147949 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C2993294228 |
| concepts[5].level | 3 |
| concepts[5].score | 0.521632730960846 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q13632630 |
| concepts[5].display_name | Thyroid carcinoma |
| concepts[6].id | https://openalex.org/C2781230642 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5158954858779907 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q492646 |
| concepts[6].display_name | Targeted therapy |
| concepts[7].id | https://openalex.org/C3018694869 |
| concepts[7].level | 4 |
| concepts[7].score | 0.4989347457885742 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q927316 |
| concepts[7].display_name | Radioiodine therapy |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.4665510356426239 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C2779761222 |
| concepts[9].level | 3 |
| concepts[9].score | 0.40869802236557007 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q826522 |
| concepts[9].display_name | Thyroid cancer |
| concepts[10].id | https://openalex.org/C502942594 |
| concepts[10].level | 1 |
| concepts[10].score | 0.391305536031723 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[10].display_name | Cancer research |
| concepts[11].id | https://openalex.org/C526584372 |
| concepts[11].level | 2 |
| concepts[11].score | 0.3758758306503296 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q16399 |
| concepts[11].display_name | Thyroid |
| concepts[12].id | https://openalex.org/C2777701055 |
| concepts[12].level | 3 |
| concepts[12].score | 0.16434022784233093 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[12].display_name | Immunotherapy |
| concepts[13].id | https://openalex.org/C121608353 |
| concepts[13].level | 2 |
| concepts[13].score | 0.1337791383266449 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[13].display_name | Cancer |
| concepts[14].id | https://openalex.org/C86803240 |
| concepts[14].level | 0 |
| concepts[14].score | 0.0851607620716095 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[14].display_name | Biology |
| concepts[15].id | https://openalex.org/C87355193 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q411 |
| concepts[15].display_name | Astrobiology |
| keywords[0].id | https://openalex.org/keywords/lenvatinib |
| keywords[0].score | 0.9501677751541138 |
| keywords[0].display_name | Lenvatinib |
| keywords[1].id | https://openalex.org/keywords/pembrolizumab |
| keywords[1].score | 0.895641565322876 |
| keywords[1].display_name | Pembrolizumab |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.697416365146637 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/refractory |
| keywords[3].score | 0.6726108193397522 |
| keywords[3].display_name | Refractory (planetary science) |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.5956301689147949 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/thyroid-carcinoma |
| keywords[5].score | 0.521632730960846 |
| keywords[5].display_name | Thyroid carcinoma |
| keywords[6].id | https://openalex.org/keywords/targeted-therapy |
| keywords[6].score | 0.5158954858779907 |
| keywords[6].display_name | Targeted therapy |
| keywords[7].id | https://openalex.org/keywords/radioiodine-therapy |
| keywords[7].score | 0.4989347457885742 |
| keywords[7].display_name | Radioiodine therapy |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.4665510356426239 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/thyroid-cancer |
| keywords[9].score | 0.40869802236557007 |
| keywords[9].display_name | Thyroid cancer |
| keywords[10].id | https://openalex.org/keywords/cancer-research |
| keywords[10].score | 0.391305536031723 |
| keywords[10].display_name | Cancer research |
| keywords[11].id | https://openalex.org/keywords/thyroid |
| keywords[11].score | 0.3758758306503296 |
| keywords[11].display_name | Thyroid |
| keywords[12].id | https://openalex.org/keywords/immunotherapy |
| keywords[12].score | 0.16434022784233093 |
| keywords[12].display_name | Immunotherapy |
| keywords[13].id | https://openalex.org/keywords/cancer |
| keywords[13].score | 0.1337791383266449 |
| keywords[13].display_name | Cancer |
| keywords[14].id | https://openalex.org/keywords/biology |
| keywords[14].score | 0.0851607620716095 |
| keywords[14].display_name | Biology |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.26926236.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.26926236.v1 |
| locations[1].id | pmh:oai:figshare.com:article/26926236 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306400572 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | OPAL (Open@LaTrobe) (La Trobe University) |
| locations[1].source.host_organization | https://openalex.org/I196829312 |
| locations[1].source.host_organization_name | La Trobe University |
| locations[1].source.host_organization_lineage | https://openalex.org/I196829312 |
| locations[1].license | cc-by |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/cc-by |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5073213708 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-8881-6543 |
| authorships[0].author.display_name | Jena D. French |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jena D. French |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5073085667 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-7005-8994 |
| authorships[1].author.display_name | Bryan R. Haugen |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Bryan R. Haugen |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5022036818 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6632-4951 |
| authorships[2].author.display_name | Francis P. Worden |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Francis P. Worden |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5088419169 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-1406-0963 |
| authorships[3].author.display_name | Daniel W. Bowles |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Daniel W. Bowles |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5017054827 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-8411-7059 |
| authorships[4].author.display_name | Andrew G. Gianoukakis |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Andrew G. Gianoukakis |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5036473043 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-9099-5990 |
| authorships[5].author.display_name | Bhavana Konda |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Bhavana Konda |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5081266559 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-3776-208X |
| authorships[6].author.display_name | Ramona Dadu |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ramona Dadu |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5061365371 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-4960-4783 |
| authorships[7].author.display_name | Eric J. Sherman |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Eric J. Sherman |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5069374156 |
| authorships[8].author.orcid | https://orcid.org/0009-0004-2245-3323 |
| authorships[8].author.display_name | Shaylene McCue |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Shaylene McCue |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5008026182 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-2874-1295 |
| authorships[9].author.display_name | Nathan R. Foster |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Nathan R. Foster |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5020353829 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-2239-1095 |
| authorships[10].author.display_name | Yuri E. Nikiforov |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Yuri E. Nikiforov |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5025144250 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-3606-2428 |
| authorships[11].author.display_name | Ticiana D.J. Farias |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Ticiana D.J. Farias |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5025812799 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-8370-7703 |
| authorships[12].author.display_name | Paul J. Norman |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Paul J. Norman |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5026698479 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-2629-2289 |
| authorships[13].author.display_name | Lori J. Wirth |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | Lori J. Wirth |
| authorships[13].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.26926236.v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Data S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10329 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9986000061035156 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Thyroid Cancer Diagnosis and Treatment |
| related_works | https://openalex.org/W4306377359, https://openalex.org/W4212931506, https://openalex.org/W3032174239, https://openalex.org/W4364353162, https://openalex.org/W3213507836, https://openalex.org/W3111895878, https://openalex.org/W4318203757, https://openalex.org/W3132967946, https://openalex.org/W4309861866, https://openalex.org/W3030532419 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1158/1078-0432.26926236.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.26926236.v1 |
| primary_location.id | doi:10.1158/1078-0432.26926236.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.26926236.v1 |
| publication_date | 2024-09-03 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W2118982164, https://openalex.org/W2161442739, https://openalex.org/W2062783581, https://openalex.org/W2039123767, https://openalex.org/W2099938880, https://openalex.org/W1480870696, https://openalex.org/W2314388990, https://openalex.org/W2164720040, https://openalex.org/W2108933323, https://openalex.org/W2168076926, https://openalex.org/W2157483153, https://openalex.org/W1967792499, https://openalex.org/W2107398170, https://openalex.org/W2032838951, https://openalex.org/W2163825883, https://openalex.org/W2169435545, https://openalex.org/W2109485845, https://openalex.org/W2108158604, https://openalex.org/W2032005362, https://openalex.org/W2044586123, https://openalex.org/W1976617226, https://openalex.org/W2073829596, https://openalex.org/W3112156481, https://openalex.org/W1986141346, https://openalex.org/W1032479178, https://openalex.org/W2151950842, https://openalex.org/W2075371626, https://openalex.org/W2144177534, https://openalex.org/W2115674896, https://openalex.org/W2046434791, https://openalex.org/W2080612883, https://openalex.org/W2106511606 |
| referenced_works_count | 32 |
| abstract_inverted_index.Trial | 1 |
| abstract_inverted_index.<p>Clinical | 0 |
| abstract_inverted_index.Protocol</p> | 2 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 14 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.550000011920929 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.25377431 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |